November 15, 2006
CureMark Announces License and Development Agreement With Balchem Corporation for Production of Its Enzyme Specialty Products
YONKERS, N.Y., Nov. 15 /PRNewswire/ -- CureMark(TM), a privately held specialty biotechnology company focused on the treatment of neurological and other diseases by addressing certain key gastrointestinal/pancreatic secretory deficiencies, announces today the signing of a licensing and development agreement to utilize Balchem Corporation's novel drug delivery technologies to optimize CureMark's proprietary enzyme formulation.
Under the agreement, Balchem has granted CureMark an exclusive license for using its patented and proprietary drug delivery technology, PharmaShure(TM) in all of CureMark's digestive/pancreatic enzyme products. CureMark has found that autistic children suffer from a pancreatic secretory deficiency and has demonstrated in empirical studies that a specific pancreatic enzyme formulation can positively impact many aspects of autism."This is a major step in our strategy of developing highly effective, stable and proprietary enzyme formulation products for the treatment of Autism and other dysautonomic diseases and disorders," said Dr. Joan Fallon, CEO of CureMark. "We recognize the need to provide a safe, stable and uniform enzyme product for patients with Autism, cystic fibrosis and other diseases. The use of PharmaShure will be a key part of our anticipated clinical trials for our lead products for autism and cystic fibrosis in 2007."
The Balchem technology is proven, unique and highly flexible encapsulation system that allows for the incorporation of multiple drug delivery features, including intestinal localization, and modified pharmacokinetic profiles.
Dino Rossi, CEO of Balchem, said, "We are confident that with the complement of Balchem's technology, CureMark will provide effective treatments for autism and other afflictions, To be on the ground-floor with CureMark in the development of novel therapies for people with special needs is a great source of pride and satisfaction for our company."
Balchem Corporation consists primarily of three business segments: ARC Specialty Products, BCP Ingredients and its Food, Pharma & Human Nutrition Division, which is one of the world's leading providers of microencapsulated ingredient solutions. The Encapsulated/Nutritional segment provides proprietary microencapsulation solutions to an expanding variety of applications. Its proprietary PharmaShure(TM) Taste-Masking and PharmaShure(TM) Modified Release technologies bring together coating chemistry, material science and cGMP manufacturing to accelerate the NDA, ANDA or OTC product development process. For more information, visit http://www.balchem.com/.
CureMark is a drug development company focused on the treatment of neurological and other diseases by addressing certain key gastrointestinal/pancreatic secretory deficiencies. These deficiencies are thought to play a role by altering the availability and absorption of key amino acids and other components that may be needed for the synthesis of neurotransmitters and possibly other agents important for the proper functioning of various organ systems including but not limited to the central nervous system. CureMark has initially focused its efforts on the development of a therapeutic product for the treatment of Autism. CureMark has a substantial patent portfolio, which it plans to commercialize in the areas of autism, ADD ADHD, Parkinson's, diabetic neuropathy and other conditions. For further information please go to http://www.cure-mark.com/.
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.
Contact: CureMark Dr. Joan Fallon 914-779-9300 [email protected]
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com/.
CONTACT: Dr. Joan Fallon of CureMark, +1-914-779-9300,[email protected]
Web site: http://www.cure-mark.com/http://www.balchem.com/